Acadian Asset Management LLC Reduces Stock Position in ChromaDex Co. (NASDAQ:CDXC)

Acadian Asset Management LLC cut its holdings in ChromaDex Co. (NASDAQ:CDXC) by 31.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,265 shares of the company’s stock after selling 6,196 shares during the period. Acadian Asset Management LLC’s holdings in ChromaDex were worth $35,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Miracle Mile Advisors LLC acquired a new stake in shares of ChromaDex during the 2nd quarter worth about $27,000. Lazard Asset Management LLC purchased a new position in ChromaDex in the first quarter valued at approximately $43,000. SG Americas Securities LLC acquired a new stake in ChromaDex during the first quarter worth approximately $54,000. Rhumbline Advisers acquired a new stake in ChromaDex during the second quarter worth approximately $124,000. Finally, Perritt Capital Management Inc. purchased a new stake in shares of ChromaDex during the 1st quarter worth approximately $139,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 9.64% of the stock is owned by insiders.

ChromaDex Trading Down 1.9 %

Shares of NASDAQ CDXC opened at $3.63 on Friday. The stock has a market cap of $274.21 million, a P/E ratio of -72.60 and a beta of 1.86. The stock has a 50 day moving average of $3.17 and a two-hundred day moving average of $3.15. ChromaDex Co. has a twelve month low of $1.25 and a twelve month high of $4.65.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CDXC. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a research report on Friday, August 9th. Roth Mkm reaffirmed a “buy” rating and set a $6.00 price objective on shares of ChromaDex in a report on Wednesday, June 12th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.